Benefits and Drawbacks of Molecular Techniques for Diagnosis of Viral Respiratory Infections. Experience With Two Multiplex PCR Assays

Laura García-Arroyo,1 Nuria Prim,1 Neus Martí,1 Maria Carme Roig,1 Ferran Navarro,1,2 and Nuria Rabella1,2*

1Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
2Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Barcelona, Spain

Molecular techniques have represented a major step forward in the diagnosis of viral respiratory infections. They are considered highly sensitive and specific compared to conventional techniques. In this study two nucleic acid amplification tests (NAATs) were compared to conventional methods (immuno-fluorescence and viral culture). The aim of this work was to discuss the clinical interpretation of the results obtained by NAATs on the basis of the two-decade experience of our group and the literature. Eighty nasopharyngeal aspirates were collected from children under six years attended for acute respiratory illness at the pediatric emergency room of a third level hospital. Both NAATs tested (Seeplex® and Clart®) showed an overall higher performance regarding sensitivity (76% and 90%, respectively). Compared to Seeplex®, the Clart® system tripled the number of multiple detections (8 by Seeplex® vs. 25 by Clart®). In some specimens both NAATs detected different viruses. Given these discrepancies and the fact that detection of viral nucleic acids is not necessarily related to the current clinical syndrome, the interpretation of molecular results may not always be so straightforward. The pros and cons of NAATs should always be taken into account when giving a result.

J. Med. Virol. 88:45–50, 2016.
© 2015 Wiley Periodicals, Inc.

KEY WORDS: multiplex PCR; respiratory virus; viral isolation; immuno-fluorescence

INTRODUCTION

Respiratory tract infections are the most frequent cause of illness in children, and most of them are of viral etiology [van de Pol et al., 2007; Mahony, 2008; Raymond et al., 2009; Vallieres and Renaud, 2013]. The most common respiratory viruses are Influenza A virus (FLUAV), Influenza B virus (FLUBV), Human parainfluenzavirus 1–4 (PIV-1-4), Human respiratory syncitial virus (RSV), Human metapneumovirus (hMPV), Enteroviruses (EV), Rhinoviruses (RV), Human coronaviruses (HCoV), Human bocaviruses (HBoV), and Human adenoviruses (AdV). As infections caused by respiratory viruses show similar clinical manifestations, microbiological studies must be performed to identify the etiology [Caliendo, 2011; Pagarolas and Sune, 2014].

Diagnosis of viral respiratory infections is traditionally performed using conventional methods based on viral culture (VC), or antigen detection such as immunofluorescence assays (IF). VC remains the gold-standard but it requires trained personnel, results may take a few days, and not all viruses can multiply in culture. IF techniques are quick and they allow quality control of samples but they need big expertise for interpretation. Additionally, they are not available for all viruses and lack sensitivity for others [Ginocchio and McAdam, 2011].

Nucleic acid amplification tests (NAATs) have become an alternative that offers high sensitivity and specificity when compared to conventional methods [Elnifro et al., 2000; Mahony, 2008; Ginocchio and McAdam, 2011]. Numerous tests have been developed using multiplex PCR to detect several viruses, including those that are not detected either by VC or by immunoassays. Although PCR-based techniques were
initially limited by the few types of viruses that could be detected in a single test [Liolios et al., 2001; Coiras et al., 2004; Bellau-Pujol et al., 2005; Freymuth et al., 2006], numerous multiplex PCR tests have been developed, allowing more than 10 viruses to be detected in a single assay. Amplicon detection can be performed by hybridization using microarrays [Henricksen et al., 2007; Raymond et al., 2009; Cannon et al., 2010; Renois et al., 2010; Frobert et al., 2011; Culebras et al., 2013; Pillet et al., 2013] or semiconductor-based DNA microspheres [Mahony et al., 2007]. Several respiratory virus panels (RVP) have been commercialized, such as xTAG® RVP from Luminex® [Mahony et al., 2007; Pabbaraju et al., 2008; Gadsby et al., 2010; Balada-Llasat et al., 2011; Kim et al., 2013; Pillet et al., 2013], Multicode PLx RVP from Eragen [Balada-Llasat et al., 2011], and Resplex® II from Qiagen [Li et al., 2007; Balada-Llasat et al., 2011; Pillet et al., 2013]. Other NAATs are the multiplex ligation-dependent probe amplification system (MLPA) [Reijans et al., 2008; Bruijnesteijn van Coppenraet et al., 2010; Pillet et al., 2013] and the dual priming oligonucleotide (DPO) system [Roh et al., 2008; Bruijnesteijn van Coppenraet et al., 2010; Zhang et al., 2012; Cho et al., 2013; Kim et al., 2013; Pillet et al., 2013]. PCR-based systems generate a diagnostic result within only one working day, but implementation in a laboratory routine may not be cost-effective.

This study assessed two multiplex PCR-based techniques commercially available, namely Clart® and Seeplex®. Both NAATs have been studied previously [Roh et al., 2008; Bruijnesteijn van Coppenraet et al., 2010; Renois et al., 2010; Frobert et al., 2011; Zhang et al., 2012; Cho et al., 2013; Culebras et al., 2013; Kim et al., 2013; Pillet et al., 2013] and, in the present work, they were compared with each other and also with two conventional methods for the diagnosis of viral respiratory infections. The aim of this work was to discuss the clinical interpretation of the results obtained by NAATs on the basis of our two-decade experience on conventional methods. The benefits and pitfalls of molecular techniques are also discussed.

**MATERIALS AND METHODS**

**Samples**

Eighty nasopharyngeal aspirates were collected from children under six years attended for acute respiratory illness at the pediatric emergency room of a third level Hospital, from October to November 2008 and from February to March 2009. Consecutive specimens, with more than 25 cells/field by microscopic observation and sufficient residual volume (300 μL), were selected. These specimens were processed within the same working day or stored at +4°C during the weekends (maximum 72 hr). Epidemiological data were collected.

**Viral Isolation and Antigen Detection**

Samples were assessed using D3 DFA Metapneumovirus Identification Kit (Diagnostics Hybrids, Athens, OH), RSV Direct IF (bioMerieux, Marcy-l’Etoile, France), and Respiratory Panel 1 Viral Screening & Identification IPA kit (Millipore, Light Diagnostics, Temecula, CA) to detect AdV, FLUAV, FLUBV, PIV-1,2,3 and RSV according to the manufacturer’s instructions. For viral isolation, these samples were cultured using six cell lines: MRC5, A549, HEp2, MDCK, LLCMK2, and RD (Vircell S.L Santa Fe, Granada, Spain). All cell cultures were examined daily for cytopathic effect during two weeks. Definitive identification was assessed by IF.

**Nucleic Acid Detection**

Nucleic acid was extracted from 200 μL of clinical samples using EZ1 Virus Mini Kit v2.0 and Bio Robot EZ-1 (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. The extracts were stored at −80°C until use. Molecular viral detection was performed using two NAATs: Seeplex® RV12 ACE Detection Kit (Seegene, Seoul, South Korea) and Clart® Pneumovir Kit (Genomica, Madrid, Spain), following the manufacturer’s instructions.

The Seeplex® method is based on the DPO system and amplicon detection is performed by fully automated capillary electrophoresis separation (MultiNA, ShimaizuBiotech, Kyoto, Japan). This method provides results in about six hours. The Clart® system is based on microarray technology and analysis of the result. The hybridization pattern is performed using optical equipment (Clondiag Chip Technologies, Jena, Germany). This method provides results in about 9 hr. Both assays detect FLUAV, FLUBV, AdV, hMPV, HCoV-229E, PIV-1, PIV-2, PIV-3, RSVa, RSVb, and RV. Seeplex® also detects HCoV-NL63 and HCoV-OC43, and differentiates between species of RV (A and B). Clart® also detects HBoV, Influenza C virus (FLUCV), EV, PIV-4 A/B, and differentiates between hMPVa and hMPVb. Both assays included an internal control to detect amplification inhibition. Both NAATs gave qualitative results only.

**Data Analysis**

Epidemiological data, such as age, sex, date of sample collection and clinical diagnosis, were collected. Statistical analyses were performed using the Vassar Stats website (http://vassarstats.net/).

In this work a result was considered clinically relevant or true positive when a respiratory virus was detected by IF and/or VC regardless of NAATs results or by both NAATs (criterion of positivity).

**RESULTS**

**Overall Viral Detection**

The range of viruses detected differed depending on the virus and the method used (Table I). Of 80
samples included in this study, viral detection was obtained in 37, 40, and 62 samples by IF/VC, Seeplex® and Clart® respectively. Either NAAT yielded a positive result in 40 samples that were negative by IF/VC. Only three samples (4%) were negative by all the techniques assessed (Table I).

Seeplex® and Clart® detected 11 and 57 viruses more than IF/VC, respectively. RVs were the viruses most frequently detected by PCR although only two were recovered by IF/VC (Table I). Multiple detection was obtained in 30 samples by NAATs while IF/VC did not achieve multiple recovery in any case. Inhibition was observed in 19 samples, 10 by Seeplex® (12.5%) and 11 by Clart® (14%); two of these samples were inhibited by both methods.

Comparison of Results Obtained By IF/VC and NAATs

According to the established criterion of positivity, 46 (57.5%) samples were considered positive for a respiratory virus; 36 by IF/VC regardless of NAAT results and 10 by two NAATs only. Viral detection was coincident between IF/VC and both NAATs in 20 samples out of 36. Coincident results were found between IF/VC and only one NAAT in 12 samples (one by Seeplex® and 11 by Clart®). Three samples had a positive viral detection by IF/VC but were negative by NAATs. Another positive sample was inhibited. In three positive samples by IF/VC, additional viruses were detected by both Seeplex® and Clart®. RV were detected in all samples positive only by both NAATs (n = 10), one of them having an additional virus (AdV). Overall, 50 significant viruses were detected. Since EVs were only detected by one NAAT, they were not included in further calculations. Considering the remaining significant viruses, the relative sensitivity of IF/VC, Seeplex® and Clart® was 70% (32/46), 76% (35/46), and 89% (41/46), respectively (Table II).

Multiple Viral Detection

NAATs achieved a high rate of multiple virus detection (37.5%; 30/80), corresponding to 10% (8/80) by Seeplex® and 31% (25/80) by Clart®. Regarding viruses identified only by one technique, Clart® detected HBoVs in 16 samples and 13 of them (81%) were multiple detections. Seeplex® detected HCoV-OC43 in five samples corresponding to multiple detections in three cases (60%). Following the criterion of positivity previously established, only four samples were considered to have real multiple infections (8.7%; 4/46) (Table III).

Clinical Analysis

Regarding clinical and demographic analysis, no relevant data were obtained. From the total number of samples assessed, 39 and 41 specimens belonged to patients with upper and lower respiratory tract infections (URTI and LRTI), respectively. The viral distribution did not follow a definite pattern although RSV and AdV were predominantly detected in patients with LRTI and URTI, respectively. No statistically significant association was found between viruses detected and each clinical group.

DISCUSSION

The main finding in the present study was that both NAATs used to detect respiratory viruses yielded different results. As expected, NAATs detected more viruses than the conventional techniques. The question remains, however, as to whether this extra sensitivity provides more reliable information about the etiology of the infection.

| Virus            | IF/VC | Seeplex® | Clart® |
|------------------|-------|----------|--------|
| RSV              | 11a   | 7        | 12     |
| AdV              | 13b   | 14       | 13     |
| EV               | 4     | ND       | 10     |
| hMPV             | 4     | 1        | 7      |
| RV               | 2     | 17       | 27     |
| PIV-3            | 2     | 4        | 4      |
| FLUBV            | 0     | 3        |        |
| HCoV-OC43        | ND    | 5        | ND     |
| HBoV             | ND    | ND       | 16     |
| PIV-4            | ND    | ND       | 1      |
| FLUCV            | ND    | ND       | 1      |
| Human herpesvirus 5 | ND | 1         | ND     |
| Total virus detected | 37 | 48       | 94     |
| Total positive samples | 37 | 40       | 62     |
| Total negative samples | 43 | 30       | 7      |
| Total inhibited samples | ND | 10       | 11     |
| Total of samples with multiple viruses | 0 | 8        | 25     |

ND, unable to be detected by the corresponding technique.

aIF and VC were positive in seven cases, and only IF in four cases.
bIF and VC were positive in one case, and only VC in 12 cases.
**TABLE II. Total of Viruses Detected By Each Technique Considering the Criterion of Positivity**

| Virus       | Total | IF/VC | Seeplex | Clart |
|-------------|-------|-------|---------|-------|
| RSV         | 11    | 11    | 7       | 10    |
| AdV         | 14    | 13    | 11      | 12    |
| PIV-3       | 2     | 2     | 2       | 2     |
| hMPV        | 4     | 4     | 1       | 3     |
| RV          | 15    | 2     | 14      | 14    |
| EV          | 4     | 4     | ND      | 4     |
| Multiple detection | 4 | 0 | 2 | 4 |
| Total of virus detected | 50 | 36 | 35 | 45 |
| Sensitivity | —    | 70%   | 76%     | 89%   |

ND, unable to be detected by the corresponding technique.
*A total of 46 viruses were considered after exclusion of EV.

Clart* had the highest detection rate and results agreed with conventional results more often than those by Seeplex*. This could be due to the different range of viruses covered by each technique. Although both NAATs have been investigated before, the methods used as gold standard were different [Roh et al., 2008; Bruijnesteijn van Coppenraet et al., 2010; Frobert et al., 2011; Zhang et al., 2012; Cho et al., 2013; Culebras et al., 2013; Kim et al., 2013; Pillet et al., 2013]. An important drawback in comparing NAATs is therefore the lack of a real gold standard.

Both conventional and PCR-based methods yielded similar results for RSV and Adv. For RSV, IF was more sensitive than VC and equally sensitive to the molecular methods. For AdV, isolation in cell cultures is usually required because of the poor sensitivity of IF and the number of AdV isolates coincided with those detected by molecular methods. These findings coincided with the experience of our group over the last two decades and have been reported by other authors [Dunn et al., 2004; Mahony, 2008; Doan et al., 2012; Cho et al., 2013].

Molecular techniques have been the key to diagnosing a large range of new viruses incapable of multiplying in VC, such as HCoV and HBov, and the new species of RV. Considering those viruses detected only by PCR, about 72% corresponded to RV, hMPV, HCoV-OC43, PIV-4, FLUCV, and HBov. As in previous studies, both NAATs largely increased the number of RV detected [Freyth et al., 2006; Li et al., 2007; Mahony et al., 2007; Bruijnesteijn van Coppenraet et al., 2010; Cho et al., 2013].

NAATs do not always give a result. Inhibition of the amplification reaction is a drawback, mainly because of the specimen itself or the extraction protocol. Both NAATs tested yielded inhibited results. The fact that most inhibited samples differed between the two techniques, despite the extract being the same, suggests that the methods were probably the main cause of PCR inhibition.

The failure of NAATs to give a result may also be because of the lack of a specific target. This is not only because the target is not included in the reaction, as in the case of Human herpesvirus 5, but also because of the variability of the respiratory viruses. Therefore laboratories, especially those that rely only on NAATs, need to constantly review the viruses included in the assays they use [Ogilvie, 2001].

NAATs have created a new scenario in the diagnosis of viral respiratory infections: the high yield of multiple viral detections [Kuyper et al., 2006; Madhi and Klugman, 2006; Leland and Ginocchio, 2007]. Compared to Seeplex*, the Clart* system tripled the number of multiple detections; differences in their design, particularly concerning the primers and the amplification conditions, may contribute to this disparity. The high rate of multiple detection, which may be explained because of the pediatric population, is in agreement with other authors [Roh et al., 2008; Kim et al., 2009; Bruijnesteijn van Coppenraet et al., 2010; Frobert et al., 2011; Zhang et al., 2012].

So an important remaining question is the clinical relevance of the results obtained by NAATs. Covering a broad range of etiological agents, these quick techniques may be especially useful in immunosuppressed or critically ill patients although their clinical impact is not yet well established [Garbino et al., 2009; Schnell et al., 2012]. However, as NAATs detect viral nucleic acids regardless of the presence of viral antigens or infective viruses [Pagarolas and Sune, Garcia-Arroyo et al.]

---

**TABLE III. All Samples With Multiple Viral Detection. Real Multiple Infections According to the Criterion of Positivity Are Shown in Bold**

| No | IF/VC | Seeplex | Clart |
|----|-------|---------|-------|
| 1  | RSV   | RSV     | RSV + HBov |
| 2  | NEG   | RV + HCoV-OC43 | RV    |
| 8  | NEG   | RV      | RV + HBov + PIV-3 |
| 10 | NEG   | RV      | RV + HBov |
| 13 | NEG   | Inhibited sample | HBov + EV + PIV-4 |
| 15 | PIV-3  | PIV-3 + RV | PIV-3 + RV |
| 17 | NEG   | PIV-3 + RV | Inhibited sample |
| 18 | EV    | RV      | RV + EV |
| 20 | AdV   | AdV     | AdV + RV |
| 21 | RSV   | RSV     | RSV + HBov |
| 22 | RSV   | RSV     | RSV + HBov |
| 23 | EV    | RV      | RV + EV |
| 26 | PIV-3 | PIV-3   | PIV-3 + HBov |
| 27 | NEG   | AdV + RV | AdV + RV + RSV |
| 29 | NEG   | NEG     | AdV + RV |
| 30 | RSV   | RSV     | RSV + HBov |
| 36 | EV    | EV      | EV + RV + HBov |
| 37 | RSV   | RSV     | RSV + EV + RV + HBov |
| 38 | RSV   | RSV     | RSV + EV + RV |
| 43 | AdV   | AdV     | AdV + HBov |
| 47 | AdV   | AdV     | AdV + FLUCV |
| 51 | AdV   | AdV + RV | AdV |
| 52 | AdV   | AdV + HCoV-OC43 | AdV |
| 55 | hMPV  | hMPV + HCoV-OC43 | hMPV + RV |
| 60 | AdV   | AdV     | AdV + HBov |
| 63 | AdV   | AdV + RV | AdV |
| 65 | AdV   | AdV     | AdV + hMPV |
| 67 | NEG   | Inhibited sample | EV + FLUBV |
| 68 | NEG   | NEG     | hMPV + HBov |
| 79 | EV    | NEG     | EV + hMPV |

*ND, unable to be detected by the corresponding technique.

**TABLE II. Total of Viruses Detected By Each Technique Considering the Criterion of Positivity**

| Virus       | Total | IF/VC | Seeplex | Clart |
|-------------|-------|-------|---------|-------|
| RSV         | 11    | 11    | 7       | 10    |
| AdV         | 14    | 13    | 11      | 12    |
| PIV-3       | 2     | 2     | 2       | 2     |
| hMPV        | 4     | 4     | 1       | 3     |
| RV          | 15    | 2     | 14      | 14    |
| EV          | 4     | 4     | ND      | 4     |
| Multiple detection | 4 | 0 | 2 | 4 |
| Total of virus detected | 50 | 36 | 35 | 45 |
| Sensitivity | —    | 70%   | 76%     | 89%   |

ND, unable to be detected by the corresponding technique.
*A total of 46 viruses were considered after exclusion of EV.
ACKNOWLEDGMENTS

The authors would like to thank Dr. Adela Retana for clinical data review, and Margarita del Cuerpo, and Oscar Cordon for their technical assistance. Kits for molecular detection of viruses were kindly provided by Genomica S.A.U. and Izasa-Werfen Group.

REFERENCES

Balada-Llasat JM, LaRue H, Kelly C, Rigali L, Pancholi P. 2011. Evaluation of commercial ResPlex II v2.0, MultiCode-PLx, and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults. J Clin Virol 50:42–45.

Bellau-Pujol S, Vabret A, Legrand L, Dina J, Gourain S, Petitjean-Lecherbonnies J, Pozzetto B, Ginnevra C, Freymuth F. 2005. Development of three multiplex RT-PCR assays for the detection of 12 respiratory RNA viruses. J Virol Methods 126:53–63.

Bruitinsteijn van Coppenraet LE, Swanink CM, van Zewt AA, Nijhuis RH, Schirm J, Wallinga JA, Ruijs GJ. 2010. Comparison of two commercial molecular assays for simultaneous detection of respiratory viruses in clinical samples using two automatic electrophoresis detection systems. J Virol Methods 169:188–192.

Buller RS, 2013. Molecular detection of respiratory viruses. Clin Microbiol Rev 26:129–159.

Caliendo AM. 2011. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 52:S326–S330.

Cannon GA, Carr MJ, Yandle Z, Schaffer K, Kidney R, Hesney G, Doyle A, Ryan J, Guinan MM, Hall WW. 2010. A low density oligonucleotide microarray for the detection of viral and atypical bacterial respiratory pathogens. J Virol Methods 163:17–24.

Coiras MT, Aguilar JC, Garcia ML, Casas I, Perez-Brena P. 2004. Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. J Med Virol 72:484–495.

Culebras E, Betriu C, Vazquez-Cid E, Lopez-Varela E, Rueda S, Picazo JJ. 2013. Detection and genotyping of human respiratory viruses in clinical specimens from children with acute respiratory tract infections. Rev Esp Quimioter 26:47–50.

Cho CH, Chultan B, Lee CK, Nam MH, Yoon SY, Lim CS, Cho Y, Kim YK. 2013. Evaluation of a novel real-time RT-PCR using TOE technology compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses. J Clin Virol 57:338–342.

Debiaggi M, Cannucci F, Ceresola E, Clementi M. 2012. The role of infections and coinfections with newly identified and emerging respiratory viruses in children. Virol J 9:247.

Doan Q, Enarson P, Kiosoos N, Klassen TP, Johnson DW. 2012. Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department. Cochrane Database Syst Rev 5:CD006452.

Dunn JJ, Woolstenhulme RD, Langer J, Carroll KC. 2004. Sensitivity of respiratory virus culture when screening with R-mix fresh cells. J Clin Microbiol 42:79–82.

Elnifro EM, Ashshi AM, Cooper RJ, Klapper PE. 2000. Multiplex PCR: Optimization and application in diagnostic virology. Clin Microbiol Rev 13:559–579.

Freymuth F, Vabret A, Cuvoillon-Nimal D, Simon S, Dina J, Legrand L, Gourain S, Petitjean J, Eckart P, Brouard J. 2006. Comparison of multiplex PCR assays and conventional techniques for the diagnostic of respiratory virus infections in children admitted to hospital with an acute respiratory illness. J Med Virol 78:1498–1504.

Frobert E, Escuret V, Javouhey E, Casalogue JS, Bouscambert-Duchamp M, Moulinier C, Gillet Y, Lina B, Floret D, Mofrin F. 2011. Respiratory viruses in children admitted to hospital intensive care units: evaluation of the CLART(R) Pneumovirus DNA array. J Med Virol 83:150–155.

Gadsby NJ, Hardie A, Claas EC, Temkton KE. 2010. Comparison of the Luminex Respiratory Virus Panel fast assay with in-house real-time PCR for respiratory viral infection diagnosis. J Clin Microbiol 48:2213–2216.

Garbino J, Soccal PM, Aubert JD, Rochat T, Meylan P, Thomas Y, Tapparel C, Briveaux PO, Kaiser L. 2009. Respiratory viruses in bronchoalveolar lavage: A hospital-based cohort study in adults. Thorax 64:399–404.

Ginocchio CC, McAdam AJ. 2011. Current best practices for respiratory virus testing. J Clin Microbiol 49:S44–S48.

Henrickson KJ, Kraft AJ, Canter D, Shaw J. 2007. Comparison of electronic microarray to enzyme hybridization assay for multiplex reverse-transcriptase PCR detection of common respiratory viruses in children. Clin Microbiol News 29:115–119.
